Shares of BiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) traded down 3.8% on Thursday . The company traded as low as $0.87 and last traded at $0.91. 62,883 shares were traded during trading, an increase of 14% from the average session volume of 55,024 shares. The stock had previously closed at $0.95.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of BiomX in a research report on Wednesday, January 8th.
Get Our Latest Analysis on BiomX
BiomX Stock Up 4.9 %
About BiomX
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
See Also
- Five stocks we like better than BiomX
- ESG Stocks, What Investors Should Know
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Financial Services Stocks Investing
- DuPont’s Electronics Spinoff: The Start of Something Big
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
